An interventional study of Hyperbaric oxygen therapy combined with polarized light therapy and traditional treatment in Neuropathic Diabetic Ulcer - Foot, sponsored by Al-Zaytoonah University of Jordan. Completed at 1 site in Egypt. Open to participants aged 55 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-22.
Sponsored by Al-Zaytoonah University of Jordan · Not applicable, Interventional, and Treatment
Neuropathic ulcers develop due to nerve damage (neuropathy), commonly seen in conditions like diabetes, leading to loss of sensation, repetitive trauma, and poor wound healing. These ulcers typically occur on weight-bearing areas, hyperbaric oxygen and polarized light therapies may have a synergistic effect, improving oxygenation, cellular activity, and overall healing outcomes in neuropathic ulcers, particularly in diabetic foot ulcers.
Al-Zaytoonah University of Jordan is the lead sponsor of 24 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
patients will evaluated to be fit for HBO therapy to ensure cardiac ejection fraction over 50% and chest CT to ensure chest free from any pathology
Other: Hyperbaric oxygen therapy combined with polarized light therapy
topical medication
Other: traditional treatment
Optimum regime of therapy increase healing rate of neuropathic foot ulcer is a challenge for researchers to save patient normal life
topical medication
Ulcer volume using Saline injection method
Time frame: 4 weeks
Tcpo2 at ulcer edge using Pulse Oximeter
Time frame: 4 weeks
Emg pre and at end (Sensory NCS (Sural nerve)
Time frame: 4 weeks
Plan to share: Undecided
No publications or documents are linked to this record.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Al-Zaytoonah University of Jordan